People · Operator
Named in public records as an officer, director or promoter · active 2009–2011 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CEBIX Inc | — | Pharmaceuticals | Series B | $76.3M | $1.1B | 2009 |
John R. Wahren at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John R. Wahren on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James I. Healy | 1 | 7 |
| Joel Martin | 1 | 5 |
| Lars G. Ekman | 1 | 3 |
| Nina G. Kjellson | 1 | 2 |
| William R. Rohn | 1 | 2 |
| Nina I. Kjellson | 1 | 1 |
| Michelle R. Morgan | 1 | 1 |
| Callaway R. James | 1 | 1 |
| David G. Kabakoff | 1 | 1 |
| William G. Rohn | 1 | 1 |
| Pratik G. Shah | 1 | 1 |
| Pratik R. Shah | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.